Gritstone Bio And Genevant Sciences Announced An Agreement Pursuant To Which Gritstone Bio Will Have A Multi-year Option For A Non-exclusive License Under Genevant's LNP Technology On A Pathogen-By-Pathogen Basis For Self-Amplifying RNA Vaccines
Portfolio Pulse from Benzinga Newsdesk
Gritstone Bio has entered into a multi-year agreement with Genevant Sciences for a non-exclusive license under Genevant's LNP technology. The license will be used on a pathogen-by-pathogen basis for self-amplifying RNA vaccines.
August 15, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The agreement with Genevant Sciences could potentially enhance Gritstone Bio's capabilities in developing self-amplifying RNA vaccines.
The agreement allows Gritstone Bio to use Genevant's LNP technology, which could potentially enhance its capabilities in developing self-amplifying RNA vaccines. This could lead to new product developments and potentially increase the company's market share and revenues in the future.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100